Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
The tainted blood tragedy is incontestably the worst public health disaster that Canada has ever faced. Today, October 27, anniversary of the creation of the...
by Zander Masser, Montreal, QC On a fall day in 1996, my parents called a family meeting. I was 11 years old. My brother was...
The CHS is announcing its Call for Applications for its research programs for the 2023-2024 grant period. The deadline to submit applications for all the...
